Nebulized Albuterol for Congestive Heart Failure Exacerbation

Last updated: October 9, 2013
Sponsor: University of California, San Francisco
Overall Status: Trial Not Available

Phase

2/3

Condition

Congestive Heart Failure

Heart Disease

Chest Pain

Treatment

N/A

Clinical Study ID

NCT01375361
RandomizedAlbuterolCHF
  • Ages 18-65
  • All Genders

Study Summary

This is a randomized trial of the use of Albuterol in the setting of acute decompensated Congestive Heart Failure with radiographic evidence of Cardiogenic Pulmonary Edema.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • age 18-65 with shortness of breath and history of CHF

  • pulmonary edema on chest xr

Exclusion

Exclusion Criteria:

  • pregnancy

  • clinical or ekg changes to suggest acute coronary syndrome

  • history of copd or asthma

  • history of albuterol on medication list

Study Design

Study Start date:
April 01, 2009
Estimated Completion Date:

Study Description

The objective is to carry out a randomized blinded placebo-controlled trial of inhaled Albuterol as an early therapy for patients with decompensated Congestive Heart Failure. Compared to placebo, inhaled Albuterol will improve oxygenation and decrease the need for non-invasive ventilation in patients with Cardiogenic Pulmonary Edema.

Connect with a study center

  • University of California

    San Francisco, California 94143
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.